Simulations Plus Inc (SLP)

Überblick Nachrichten Preisverlauf Optionskette Financials Warum fällt SLP? Forum Prognose Aktiensplit Dividendenhistorie

Schlusskurs vom Vortag:

24-Stunden-Volumen:

Relative Volume:

Marktkapitalisierung:

Nettoeinkommen (Verlust:

Netto-Cashflow:

1W Leistung:

1M Leistung:

6M Leistung:

1J Leistung:

1-Tages-Spanne:

1-Wochen-Bereich:

52-Wochen-Spanne:

Simulations Plus Inc Stock (SLP) Company Profile

Simulations Plus Inc

Healthcare (1200)

661-723-7723

42505 10TH STREET WEST, LANCASTER, CA

@SimulationsPlus

Nächster Verdiensttermin

Neueste SEC-Einreichungen

SLP's Discussions on Twitter

Vergleichen Sie SLP mit anderen Aktien

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
SLP Simulations Plus Inc	31.82	638.14M	66.98M	9.65M	10.19M	0.50
VEEV Veeva Systems Inc	226.76	36.93B	2.57B	615.26M	996.76M	3.32
SOLV Solventum Corp	72.48	12.43B	8.26B	66.00M	1.17B	0.00
TEM Tempus Ai Inc	62.98	10.01B	640.44M	-743.28M	-206.93M	0.00
DOCS Doximity Inc	53.39	9.94B	493.63M	160.55M	162.20M	0.55
HQY Healthequity Inc	102.47	8.91B	1.10B	105.67M	-197.98M	0.1475

Simulations Plus Inc Stock (SLP) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2024-11-15	Eingeleitet	Stephens	Overweight
2024-07-29	Eingeleitet	KeyBanc Capital Markets	Overweight
2024-07-16	Eingeleitet	JMP Securities	Mkt Perform
2024-06-28	Eingeleitet	William Blair	Outperform
2023-05-09	Eingeleitet	BTIG Research	Buy
2021-10-26	Hochstufung	Craig Hallum	Hold → Buy
2021-01-12	Herabstufung	Craig Hallum	Buy → Hold
2020-10-16	Eingeleitet	Raymond James	Outperform
2020-09-08	Eingeleitet	Oppenheimer	Outperform
2020-01-06	Eingeleitet	Craig Hallum	Buy

Alle ansehen

Simulations Plus Inc Aktie (SLP) Neueste Nachrichten

Finanzdaten der Simulations Plus Inc-Aktie (SLP)

Simulations Plus Inc-Aktie (SLP) Insiderhandel

Insiderhandel	Beziehung	Datum	Transaktion	Kosten	#Aktien	Wert ($)	#Aktien Gesamt
WOLTOSZ WALTER S	Director	Oct 01 '24	Sale	31.26	20,000	625,200	3,481,592
WEINER DANIEL L	Director	Sep 27 '24	Sale	31.54	750	23,655	6,994

Simulations Plus Inc (SLP)

Simulations Plus Inc Stock (SLP) Company Profile

Vergleichen Sie SLP mit anderen Aktien

Simulations Plus Inc Stock (SLP) Upgrades & Downgrades

Simulations Plus Inc Aktie (SLP) Neueste Nachrichten

Wall Street Analysts Predict a 56.99% Upside in Simulations Plus (SLP): Here's What You Should Know - Yahoo Finance

JMP Securities Initiates Coverage of Simulations Plus (SLP) with Market Perform Recommendation - MSN

Simulations Plus (NASDAQ:SLP) Stock Price Up 7.8%Here's Why - MarketBeat

Principal Financial Group Inc. Buys 2,226 Shares of Simulations Plus, Inc. (NASDAQ:SLP) - Defense World

Detailed Analysis of Molecular Modeling for Drug Development - openPR

Uncovering the Future: Pharmaceutical Simulation Software - openPR

Simulations Plus (SLP) Stock Jumps 8.9%: Will It Continue to Soar? - Yahoo Finance

Simulations Plus stock hits 52-week low at $27.2 amid market shifts - Investing.com Canada

Simulations Plus stock hits 52-week low at $27.2 amid market shifts By Investing.com - Investing.com South Africa

How Much Upside is Left in Simulations Plus (SLP)? Wall Street Analysts Think 77.52% - MSN

Simulations Plus to Participate in the BTIG Digital Health Forum - BioSpace

Biosimulation Market Dynamics and Future Opportunities | 2024 - openPR

Simulations Plus, Inc. (NASDAQ:SLP) Given Consensus Rating of “Buy” by Brokerages - Defense World

Royce & Associates LP Acquires 53,092 Shares of Simulations Plus, Inc. (NASDAQ:SLP) - MarketBeat

Simulations Plus, Inc. (NASDAQ:SLP) Receives $51.40 Average PT from Brokerages - MarketBeat

Simulations Plus (NASDAQ:SLP) Upgraded at Stephens - MarketBeat

Simulations Plus, Inc. (NASDAQ:SLP) Shares Bought by US Bancorp DE - Defense World

Simulations Plus (NASDAQ:SLP) Now Covered by Analysts at Stephens - MarketBeat

Where are the Opportunities in (SLP) - Stock Traders Daily

Simulations Plus Inc (SLP) Shares Gap Down to $30.515 on Nov 14 - GuruFocus.com

Simulations Plus Wins FDA Grant for Revolutionary Drug Delivery Modeling Technology | SLP Stock News - StockTitan

Simulations Plus and the University of Connecticut Receive New FDA Grant to Expand Mechanistic Modeling Approaches for Long-Acting Injectables - Business Wire

Biosimulation Market on Track for Strong Growth by 2031 | Certara, Simulations Plus Inc, Rhenovia Pharma - openPR

William Blair Issues Positive Forecast for SLP Earnings - Defense World

William Blair Boosts Earnings Estimates for Simulations Plus - MarketBeat

We Think Simulations Plus' (NASDAQ:SLP) Healthy Earnings Might Be Conservative - Simply Wall St

Q1 EPS Forecast for Simulations Plus Raised by Analyst - MarketBeat

We Think Simulations Plus' (NASDAQ:SLP) Solid Earnings Are Understated - Yahoo Finance

Simulations Plus to Participate in the Stephens Annual Investment Conference - Business Wire

Simulations Plus (NASDAQ:SLP) Given "Outperform" Rating at William Blair - MarketBeat

StockNews.com Downgrades Simulations Plus (NASDAQ:SLP) to Sell - Defense World

Insider Sale: Director and 10% Owner Walter Woltosz Sells 20,000 Shares of Simulations Plus Inc (SLP) - GuruFocus.com

Simulations Plus, Inc. (NASDAQ:SLP) Director Sells $553,200.00 in Stock - MarketBeat

Simulations Plus director Walter Woltosz sells $553,200 in stock - Investing.com

Simulations Plus director Walter Woltosz sells $553,200 in stock By Investing.com - Investing.com UK

Simulations Plus (NASDAQ:SLP) Stock Rating Lowered by StockNews.com - MarketBeat

Conestoga Capital Advisors LLC Trims Stock Position in Simulations Plus, Inc. (NASDAQ:SLP) - MarketBeat

Simulations Plus Halts Dividends to Boost Long-Term Growth: What It Means for Investors - Nasdaq

Simulations Plus secures FDA grant for drug testing tech By Investing.com - Investing.com Canada

Simulations Plus (NASDAQ:SLP) Sets New 12-Month LowTime to Sell? - MarketBeat

Simulations Plus stock hits 52-week low at $29.32 amid market shifts - Investing.com

Simulations Plus secures FDA grant for drug testing tech - Investing.com

Simulations Plus and Partners Awarded New FDA Grant to Validate In Vitro-In Vivo Extrapolation Methods for Complex Formulations - The Bakersfield Californian

Biosimulation Market is expected to Double Its Size by Upcoming - openPR

Tributary Capital Management LLC Buys 115,122 Shares of Simulations Plus, Inc. (NASDAQ:SLP) - MarketBeat

Q2 Earnings Forecast for SLP Issued By William Blair - Defense World

Brokers Offer Predictions for SLP Q2 Earnings - MarketBeat

Simulations Plus, Inc. (NASDAQ:SLP) Receives $56.00 Consensus Price Target from Analysts - Defense World

Simulations Plus' Q4 Earnings Top Estimates on Solid Revenue Growth - MSN

Simulations Plus (NASDAQ:SLP) Posts Earnings Results, Beats Expectations By $0.02 EPS - MarketBeat

Finanzdaten der Simulations Plus Inc-Aktie (SLP)

Umsatz

Nettogewinn

Free Cashflow

ENV

Simulations Plus Inc-Aktie (SLP) Insiderhandel

Ähnlich wie SLP